Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Perou

Showing results (441-450 of 476) with videos related to

Pageof 48
Sort By:
Cancer Cell|February 5, 2010
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom, et al.
Cancer Discovery|June 18, 2016
Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung CancerHaikuo Zhang, Jun Qi, Jaime M Reyes, et al.
The Lancet. Oncology|November 5, 2020
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationAleix Prat, Valentina Guarneri, Laia Paré, et al.
Medrxiv : the Preprint Server for Health Sciences|September 5, 2025
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast CancerFrederick M Howard, James Dolezal, Hanna Hieromnimon, et al.
Cell|August 12, 2014
Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of originKatherine A Hoadley, Christina Yau, Denise M Wolf, et al.
Breast Cancer Research and Treatment|December 27, 2011
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Laura J Esserman, Donald A Berry, Maggie C U Cheang, et al.
Nature|June 3, 2016
Proteogenomics connects somatic mutations to signalling in breast cancerPhilipp Mertins, D R Mani, Kelly V Ruggles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2018
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus DocetaxelPriyanka Sharma, Sara López-Tarruella, José Angel García-Saenz, et al.
The Lancet. Oncology|July 17, 2025
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysisGuillermo Villacampa, Tomás Pascual, Paolo Tarantino, et al.
Molecular & Cellular Proteomics : MCP|December 4, 2015
An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in CancerKelly V Ruggles, Zuojian Tang, Xuya Wang, et al.
Pageof 48

Showing results (441-450 of 476) with videos related to

Sort By:
Pageof 48
Cancer Cell|February 5, 2010
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom, et al.
Cancer Discovery|June 18, 2016
Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung CancerHaikuo Zhang, Jun Qi, Jaime M Reyes, et al.
The Lancet. Oncology|November 5, 2020
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationAleix Prat, Valentina Guarneri, Laia Paré, et al.
Medrxiv : the Preprint Server for Health Sciences|September 5, 2025
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast CancerFrederick M Howard, James Dolezal, Hanna Hieromnimon, et al.
Cell|August 12, 2014
Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of originKatherine A Hoadley, Christina Yau, Denise M Wolf, et al.
Breast Cancer Research and Treatment|December 27, 2011
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Laura J Esserman, Donald A Berry, Maggie C U Cheang, et al.
Nature|June 3, 2016
Proteogenomics connects somatic mutations to signalling in breast cancerPhilipp Mertins, D R Mani, Kelly V Ruggles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2018
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus DocetaxelPriyanka Sharma, Sara López-Tarruella, José Angel García-Saenz, et al.
The Lancet. Oncology|July 17, 2025
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysisGuillermo Villacampa, Tomás Pascual, Paolo Tarantino, et al.
Molecular & Cellular Proteomics : MCP|December 4, 2015
An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in CancerKelly V Ruggles, Zuojian Tang, Xuya Wang, et al.
Pageof 48